Compare Howmet Aerospace Inc (HWM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Neurocrine Biosciences Inc — how do they compare? Howmet Aerospace Inc trades at $225.99 (market cap $88.76B), while Neurocrine Biosciences Inc trades at $142.87 (market cap $14.36B). The key difference: Howmet Aerospace Inc is far larger — about 6.2× Neurocrine Biosciences Inc's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Neurocrine Biosciences Inc for 23 Days on average.
| HWM | NBIX | |
|---|---|---|
Market Cap | $88.76B | $14.36B |
Volume | 2,648,516 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $292.65 | $185.50 |
52-Week Low | $184.09 | $123.10 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $92.86B | $14.37B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.50, up 1.26% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 20.52% net income margin and 34.89% ROE. Recent news highlights defense aerospace demand driving revenue growth, while institutional interest remains strong with Nykredit's $44.69 million investment in Q2 2026.
Outlook remains positive with 84% analyst buy ratings and $328.10 consensus price target suggesting 45% upside. Key risks include supply chain pressures and competitive threats from SpaceX's in-house initiatives. Earnings growth and defense contracts position HWM for sustained performance despite near-term technical weakness.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
